Securities code: 300261 securities abbreviation: Aba Chemicals Corporation(300261) Announcement No.: 2022-002 Aba Chemicals Corporation(300261)
Announcement on the verification results of suspension and resumption of trading of the company’s shares
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions. Special tips:
1. The trading of the company’s shares will resume from the opening of the market on Thursday, January 6, 2022.
2. According to the research results published in Science (DOI: 10.1126 / science. Abl4784) and the report “focus on Pfizer covid-19 Drug Intermediates – isopentenol and inulin” published by China International Capital Corporation Limited(601995) chemical team on December 3, 2021, carbonic anhydride and its derivatives can be used to synthesize Pfizer covid-19 oral drug palovide from the process flow. The company has a synthetic process patent for the synthesis of carbonic anhydride (Patent No.: ZL. 201410364816.2), and there are other synthetic processes for the synthesis of carbonic anhydride. According to the above report of China International Capital Corporation Limited(601995) : “carbonic anhydride can be obtained by oxidation and cyclization of inulin acid or isopentenol (3-methyl-2-butene-1-alcohol) As raw material, cyclopropane is produced, oxidized, degraded and cyclized. According to the preliminary calculation of the existing literature, we believe that the unit consumption of carbonic anhydride for the synthesis of pf-07321332 is 1.8-2.0; If the inulin route is adopted, the unit consumption of inulin is 3.5-4; If the isopentenol route is adopted, the unit consumption of isopentenol is 2.2-2.5 “. Pf-07321332 is the raw material of Pfizer’s anti covid-19 virus drug palovide. The above report of China International Capital Corporation Limited(601995) also lists the relevant conditions of the synthesis process of carbonic anhydride of three other companies in China. Due to the large number of chemical enterprises in China, it is not ruled out that other companies have the synthesis process route of carbonic anhydride other than the above. The company is not the only manufacturer in China that has the synthesis process of Caron anhydride and its derivatives. Please pay attention to investment risks, make prudent decisions and invest rationally.
3. As of the reply date of this letter of concern, the company has not signed any cooperation agreement with Pfizer, has no cooperative relationship with Pfizer, and has not supplied carlon anhydride and its derivatives to Pfizer. The customers of the company’s carbonic anhydride and its derivatives are mainly Chinese customers and Indian customers. It is uncertain whether the company’s carbonic anhydride and its derivatives are indirectly supplied to Pfizer. Please pay attention to investment risks, make prudent decisions and invest rationally.
4. As of December 31, 2021, the company’s sales of carbonic anhydride and its derivatives in 2021
The revenue is 27.073 million yuan (excluding tax), accounting for about 1% – 2% of the company’s total operating revenue in 2021, which is relatively small, and is not expected to have a significant impact on the company’s performance in 2021; As of December 31, 2021, the total amount of orders on hand for carbonic anhydride and its derivatives is 63.5408 million yuan (excluding tax), which is not expected to have a significant impact on the company’s performance in 2022. If the market demand of the company’s carbonic anhydride and its derivatives changes in the future, and the orders, sales or profit contribution meet the information disclosure standards, the company will earnestly perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please pay attention to investment risks, make prudent decisions and invest rationally.
5. As of the disclosure date of this announcement, the main structure of a2w CBD medical product production workshop has been basically completed, equipment installation and application for GMP certification are under way, and no CBD medical products have been produced and sold this year. The designed capacity of CBD medical products of the company is 700 kg / year of cannabinoid (CBD) and tetrahydrocannabinol (THC) extracts and 400000 bottles of 30ml preparation products. Affected by the epidemic in Europe, the company expects that the CBD medical products of a2w will be officially put into operation in the first quarter of 2023, and will not bring any sales revenue and profit contribution to the company in 2021 and 2022, and will not have a significant impact on the financial and operating conditions of the company in 2021 and 2022. If the overseas epidemic continues to spread, the construction progress of a2w production workshop is less than expected, and the GMP certification process of a2w is uncertain, the above situations may affect the production progress of CBD medical products, resulting in uncertainty in the production capacity and production time; If the supply and demand situation of CBD market changes in the future, it will have an adverse impact on the project; A2w is a newly established overseas company, which may face market risks, changes in national policies and other risks in the actual operation process. Please pay attention to investment risks, make prudent decisions and invest rationally. 6. From December 20, 2021 to December 28, 2021, the closing price of the company’s stock has increased by 105.66% in total. According to Article 4.3 of the special provisions on GEM trading of Shenzhen Stock Exchange, the above circumstances belong to serious abnormal fluctuations in stock trading. The increase of the company’s share price is significantly higher than the change of the company’s fundamentals, which does not match the company’s current fundamentals. The company solemnly reminds investors to pay attention to investment risks, make prudent decisions and invest rationally.
1、 Description of suspension and resumption of trading of the company’s shares
The stock trading price of Aba Chemicals Corporation(300261) (hereinafter referred to as “the company”) has increased by 105.66% from the closing price for seven consecutive trading days from December 20, 2021 to December 28, 2021. According to Article 4.3 of the special provisions on GEM trading of Shenzhen Stock Exchange, the above circumstances belong to serious abnormal fluctuations in stock trading.
Due to the recent serious abnormal fluctuation of the company’s share price, in order to safeguard the interests of the majority of investors, the company will check the serious abnormal fluctuation of stock trading in accordance with article 8.1.2 of the GEM Listing Rules of Shenzhen Stock Exchange (revised in December 2020). Upon the application of the company, the trading of the company’s shares (stock abbreviation: Aba Chemicals Corporation(300261) , stock code: 300261) shall be suspended from the opening of the market on December 29, 2021, and shall be resumed after the disclosure of the verification announcement.
During the suspension, the company checked the matters related to the abnormal fluctuation of stock trading. In view of the completion of relevant self-examination, according to the Listing Rules of gem shares of Shenzhen Stock Exchange and other regulations, upon the application of the company, the trading of the company’s shares will resume from the opening of the market on Thursday, January 6, 2022.
2、 The company pays attention to and verifies relevant information
In view of the serious abnormal fluctuation of the company’s shares, the board of directors of the company verified the controlling shareholders, shareholders holding more than 5% shares, all directors, supervisors and senior managers of the company through telephone and communication. The relevant information is described as follows:
1. Recently, the company’s business situation and internal and external business environment have not changed significantly.
2. According to the research results published in Science (DOI: 10.1126 / science. Abl4784) and the report “focus on Pfizer covid-19 Drug Intermediates – isopentenol and inulin” published by China International Capital Corporation Limited(601995) chemical team on December 3, 2021, carbonic anhydride and its derivatives can be used to synthesize Pfizer covid-19 oral drug palovide from the process flow. Process flow diagram of palovide API (simplified version)
Note: there are 18 reactions in the synthetic process of palovide API. The above is a simplified process flow chart to illustrate the specific relationship between carbonic anhydride and its derivatives and palovide API.
The company has a synthetic process patent for the synthesis of carbonic anhydride (Patent No.: ZL. 201410364816.2), and there are other synthetic processes for the synthesis of carbonic anhydride. According to the above report of China International Capital Corporation Limited(601995) : “carbonic anhydride can be obtained by oxidation and cyclization of inulin acid or isopentenol (3-methyl-2-butene-1-alcohol) As raw material, cyclopropane is produced, oxidized, degraded and cyclized. According to the preliminary calculation of the existing literature, we believe that the unit consumption of carbonic anhydride for the synthesis of pf-07321332 is 1.8-2.0; If the inulin route is adopted, the unit consumption of inulin is 3.5-4; If the isopentenol route is adopted, the unit consumption of isopentenol is 2.2-2.5 “. Pf-07321332 is the raw material of Pfizer’s anti covid-19 virus drug palovide. The above report of China International Capital Corporation Limited(601995) also lists the relevant conditions of the synthesis process of carbonic anhydride of three other companies in China. Due to the large number of chemical enterprises in China, it is not ruled out that other companies have the synthesis process route of carbonic anhydride other than the above. The company is not the only manufacturer in China that has the synthesis process of Caron anhydride and its derivatives. Please pay attention to investment risks, make prudent decisions and invest rationally.
3. As of the reply date of this letter of concern, the company has not signed any cooperation agreement with Pfizer, has no cooperative relationship with Pfizer, and has not supplied carlon anhydride and its derivatives to Pfizer. The customers of the company’s carbonic anhydride and its derivatives are mainly Chinese customers and Indian customers. It is uncertain whether the company’s carbonic anhydride and its derivatives are indirectly supplied to Pfizer. Please pay attention to investment risks, make prudent decisions and invest rationally.
4. As of December 31, 2021, the company’s sales revenue of carbonic anhydride and its derivatives in 2021 is 27.073 million yuan (excluding tax), accounting for about 1% – 2% of the company’s total operating revenue in 2021, which is relatively small, and is not expected to have a significant impact on the company’s performance in 2021; As of December 31, 2021, the total amount of orders on hand for carbonic anhydride and its derivatives is 63.5408 million yuan (excluding tax), which is not expected to have a significant impact on the company’s performance in 2022. If the market demand of the company’s carbonic anhydride and its derivatives changes in the future, and the orders, sales or profit contribution meet the information disclosure standards, the company will earnestly perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please pay attention to investment risks, make prudent decisions and invest rationally.
5. As of the disclosure date of this announcement, the main structure of a2w CBD medical product production workshop has been basically completed, equipment installation and application for GMP certification are under way, and no CBD medical products have been produced and sold this year. The designed capacity of CBD medical products of the company is 700 kg / year of cannabinoid (CBD) and tetrahydrocannabinol (THC) extracts and 400000 bottles of 30ml preparation products. Affected by the epidemic in Europe, the company expects that the CBD medical products of a2w will be officially put into operation in the first quarter of 2023, and will not bring any sales revenue and profit contribution to the company in 2021 and 2022, and will not have a significant impact on the financial and operating conditions of the company in 2021 and 2022. If the overseas epidemic continues to spread, the construction progress of a2w production workshop is less than expected, and the GMP certification process of a2w is uncertain, the above situations may affect the production progress of CBD medical products, resulting in uncertainty in the production capacity and production time; If the supply and demand situation of CBD market changes in the future, it will have an adverse impact on the project; A2w is a newly established overseas company, which may face market risks, changes in national policies and other risks in the actual operation process. Please pay attention to investment risks, make prudent decisions and invest rationally.
6. From December 20, 2021 to December 28, 2021, the closing price of the company’s stock has increased by 105.66% in total. According to Article 4.3 of the special provisions on GEM trading of Shenzhen Stock Exchange, the above circumstances belong to serious abnormal fluctuations in stock trading. The increase of the company’s share price is significantly higher than the change of the company’s fundamentals, which does not match the company’s current fundamentals. The company solemnly reminds investors to pay attention to investment risks, make prudent decisions and invest rationally.
7. There is no need to correct or supplement the information disclosed by the company in the early stage.
8. The company, its controlling shareholders and actual controllers do not have any major events that should be disclosed but not disclosed, nor do they have any major events in the planning stage.
9. During the period of serious abnormal stock fluctuation, the controlling shareholder and actual controller of the company do not buy or sell the company’s shares.
3、 Whether the company has information that should be disclosed but not disclosed
The board of directors of the company confirms that there is no undisclosed matter or planning, negotiation, intention, agreement, etc. related to the matter that should be disclosed in accordance with the Listing Rules of GEM stocks of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares and their derivatives that should be disclosed in accordance with the Shenzhen Stock Exchange GEM Listing Rules and other relevant provisions; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips deemed necessary by the company
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The company solemnly reminds investors that the stock price of the company rises greatly in the short term, and the P / E ratio is higher than the average level of the same industry. The company reminds investors that the stock price trend of the secondary market is affected by multiple factors. The stock price of the company rises higher in the short term, deviates greatly from the gem composite index in the same period, and is higher than the rise of the industry sector and comparable listed companies in the same industry in the same period. The company reminds investors to pay attention to the transaction risk and speculation risk of the secondary market. Investors should pay attention to investment risks, make prudent decisions and invest rationally.
3. On December 30, 2021, the company received the notice on Aba Chemicals Corporation(300261) issued by Shenzhen Stock Exchange (GEM notice [2021] No. 543). The company will complete the relevant reply to the attention letter as soon as possible. Please pay attention to the investment risk.
4. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations.
5. The information disclosure media designated by the company are the securities times and cninfo. Com. The information about the company shall be subject to the information published in the above designated media. Please invest rationally. Note
